Literature DB >> 21946335

Age-dependent neurovascular abnormalities and altered microglial morphology in the YAC128 mouse model of Huntington disease.

Sonia Franciosi1, Jae K Ryu, Yaein Shim, Austin Hill, Colum Connolly, Michael R Hayden, James G McLarnon, Blair R Leavitt.   

Abstract

Central nervous system (CNS) inflammatory processes including microglial activation have been implicated in the pathogenesis of neurodegenerative diseases such as Huntington Disease (HD). We report age-dependent changes in striatal microglial morphology and vasculature in the YAC128 mouse model of HD. Decreases in microglial ramification along with a decrease in vessel diameter and increased vessel density and length suggest the presence of microgliosis and proangiogenic activity in YAC128 mice. Our hypothesis for this study was that the changes in microglial morphology and perturbations in vasculature may be involved in the pathogenesis of HD and that peripheral challenge with the bacterial endotoxin, lipopolysaccharide (LPS), will exacerbate these microglial and vascular changes as well as the HD phenotype in YAC128 mice at 12 months. Chronic peripheral LPS (1mg/kg) potentiated microglial activation indicated by an increase in microglial cell body size and retraction of processes. This potentiation in microglial activation with chronic peripheral LPS challenge was paralleled with vascular remodeling including dilatation, increased vessel wall thickness, increased BBB permeability and fibrinogen deposition in YAC128 striatum. Although peripheral LPS caused an increase in microglial activation and degenerative changes in cerebrovasculature, the phenotypic hallmarks of HD in YAC128 mice such as motor coordination deficits and decreased striatal volume were not exacerbated by chronic peripheral LPS exposure. This study identifies age-dependent increases in microglial activation and angiogenesis in YAC128 at 12 months. Peripheral inflammation induced by chronic LPS causes similar changes but does not influence the HD phenotype in YAC128 mice.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21946335     DOI: 10.1016/j.nbd.2011.09.003

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  42 in total

Review 1.  The choreography of neuroinflammation in Huntington's disease.

Authors:  Andrea Crotti; Christopher K Glass
Journal:  Trends Immunol       Date:  2015-05-20       Impact factor: 16.687

2.  Reduced bioavailable manganese causes striatal urea cycle pathology in Huntington's disease mouse model.

Authors:  Terry Jo V Bichell; Michal Wegrzynowicz; K Grace Tipps; Emma M Bradley; Michael A Uhouse; Miles Bryan; Kyle Horning; Nicole Fisher; Karrie Dudek; Timothy Halbesma; Preethi Umashanker; Andrew D Stubbs; Hunter K Holt; Gunnar F Kwakye; Andrew M Tidball; Roger J Colbran; Michael Aschner; M Diana Neely; Alba Di Pardo; Vittorio Maglione; Alexander Osmand; Aaron B Bowman
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-02-16       Impact factor: 5.187

Review 3.  Translation of MicroRNA-Based Huntingtin-Lowering Therapies from Preclinical Studies to the Clinic.

Authors:  Jana Miniarikova; Melvin M Evers; Pavlina Konstantinova
Journal:  Mol Ther       Date:  2018-02-08       Impact factor: 11.454

Review 4.  Role of Microglia in Neurological Disorders and Their Potentials as a Therapeutic Target.

Authors:  Li Du; Ying Zhang; Yang Chen; Jie Zhu; Yi Yang; Hong-Liang Zhang
Journal:  Mol Neurobiol       Date:  2016-11-09       Impact factor: 5.590

5.  Mutant Huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors.

Authors:  Andrea Crotti; Christopher Benner; Bilal E Kerman; David Gosselin; Clotilde Lagier-Tourenne; Chiara Zuccato; Elena Cattaneo; Fred H Gage; Don W Cleveland; Christopher K Glass
Journal:  Nat Neurosci       Date:  2014-03-02       Impact factor: 24.884

6.  A small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington's disease.

Authors:  Danielle A Simmons; Nadia P Belichenko; Tao Yang; Christina Condon; Marie Monbureau; Mehrdad Shamloo; Deqiang Jing; Stephen M Massa; Frank M Longo
Journal:  J Neurosci       Date:  2013-11-27       Impact factor: 6.167

Review 7.  Prospects for neuroprotective therapies in prodromal Huntington's disease.

Authors:  Abhishek Chandra; Ashu Johri; M Flint Beal
Journal:  Mov Disord       Date:  2014-02-26       Impact factor: 10.338

Review 8.  MRI techniques to measure arterial and venous cerebral blood volume.

Authors:  Jun Hua; Peiying Liu; Tae Kim; Manus Donahue; Swati Rane; J Jean Chen; Qin Qin; Seong-Gi Kim
Journal:  Neuroimage       Date:  2018-02-16       Impact factor: 6.556

9.  Short-term effects of an endotoxin on substantia nigra dopamine neurons.

Authors:  Kaela R S Reinert; Claudia D Umphlet; Ariana Quattlebaum; Heather A Boger
Journal:  Brain Res       Date:  2014-02-08       Impact factor: 3.252

10.  Behavioral and monoamine perturbations in adult male mice with chronic inflammation induced by repeated peripheral lipopolysaccharide administration.

Authors:  Saritha Krishna; Celia A Dodd; Nikolay M Filipov
Journal:  Behav Brain Res       Date:  2016-01-21       Impact factor: 3.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.